Want to see INCY full AI Analyst Report?

Incyte (INCY) Stock Forecast & Price Target

1,978 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INCY Analyst Ratings

Moderate Buy

11 Buy

10 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$131.70

▲(2.79% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $131.70 with a high forecast of $157.00 and a low forecast of $104.00. The average price target represents a 2.79% change from the last price of $128.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"85":"$85","158":"$158","103.25":"$103.3","121.5":"$121.5","139.75":"$139.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$157.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$131.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$104.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[85,103.25,121.5,139.75,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.14,120.20615384615385,123.27230769230769,126.33846153846154,129.4046153846154,132.47076923076924,135.53692307692307,138.6030769230769,141.66923076923078,144.73538461538462,147.80153846153846,150.86769230769232,153.93384615384616,{"y":157,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.14,118.26,119.38,120.5,121.61999999999999,122.74,123.86,124.97999999999999,126.1,127.22,128.34,129.45999999999998,130.57999999999998,{"y":131.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.14,116.12923076923077,115.11846153846155,114.1076923076923,113.09692307692308,112.08615384615385,111.07538461538462,110.06461538461538,109.05384615384615,108.04307692307692,107.0323076923077,106.02153846153846,105.01076923076923,{"y":104,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.59,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.81,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.01,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.14,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$157.00

Average Price Target$131.70

Lowest Price Target$104.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

$105→$115

Hold

-10.24%

Downside

Reiterated

10/14/26

Incyte price target raised to $115 from $105 at TruistIncyte price target raised to $115 from $105 at Truist

Etzer Darout

Barclays

$139

Buy

8.49%

Upside

Reiterated

10/13/26

Barclays Keeps Their Buy Rating on Incyte (INCY)

Mitchell Kapoor

H.C. Wainwright

$152

Buy

18.64%

Upside

Reiterated

10/13/26

Incyte Buy Rating Reiterated as KRAS G12D Asset Shows Differentiated Efficacy; $152 Price Target Maintained

Derek Archila

Wells Fargo

$128

Hold

-0.09%

Downside

Reiterated

10/12/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Pfizer (NYSE: PFE) and Incyte (NASDAQ: INCY)

Evan Seigerman

BMO Capital

$130

Hold

1.47%

Upside

Reiterated

10/12/26

BMO Capital Keeps Their Hold Rating on Incyte (INCY)

Tazeen Ahmad

Bank of America Securities

$140

Buy

9.27%

Upside

Reiterated

10/09/26

Incyte (INCY) Receives a Buy from Bank of America Securities

Brian Abrahams

RBC Capital

$109→$114

Hold

-11.02%

Downside

Reiterated

10/08/26

Incyte price target raised to $114 from $109 at RBC CapitalIncyte price target raised to $114 from $109 at RBC Capital

Stephen Willey

Stifel Nicolaus

$145→$157

Buy

22.54%

Upside

Reiterated

10/05/26

Incyte price target raised to $157 from $145 at StifelIncyte price target raised to $157 from $145 at Stifel

John Newman

Canaccord Genuity

$152

Buy

18.64%

Upside

Reiterated

10/01/26

Analysts Conflicted on These NA Names: Incyte (NASDAQ: INCY), Howard Hughes Holdings (NYSE: HHH) and Factset Research (NYSE: FDS)

Jessica Fye

J.P. Morgan

$120→$123

Hold

-4.00%

Downside

Reiterated

09/28/26

J.P. Morgan Reaffirms Their Hold Rating on Incyte (INCY)

Jeffrey Walch

Bernstein

$104

Hold

-18.83%

Downside

Reiterated

09/25/26

Incyte (INCY) Gets a Hold from Bernstein

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/19/26

Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties

Allison Bratzel

Piper Sandler

$110→$130

Buy

1.47%

Upside

Reiterated

08/17/26

Incyte price target raised to $130 from $110 at Piper SandlerIncyte price target raised to $130 from $110 at Piper Sandler

Andrew Berens

Leerink Partners

$131→$155

Buy

20.98%

Upside

Reiterated

08/03/26

Incyte price target raised to $155 from $131 at LeerinkIncyte price target raised to $155 from $131 at Leerink

Salim Syed

Mizuho Securities

$121→$137

Buy

6.93%

Upside

Reiterated

08/03/26

Mizuho Securities Remains a Buy on Incyte (INCY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

$105→$115

Hold

-10.24%

Downside

Reiterated

10/14/26

Incyte price target raised to $115 from $105 at TruistIncyte price target raised to $115 from $105 at Truist

Etzer Darout

Barclays

$139

Buy

8.49%

Upside

Reiterated

10/13/26

Barclays Keeps Their Buy Rating on Incyte (INCY)

Mitchell Kapoor

H.C. Wainwright

$152

Buy

18.64%

Upside

Reiterated

10/13/26

Incyte Buy Rating Reiterated as KRAS G12D Asset Shows Differentiated Efficacy; $152 Price Target Maintained

Derek Archila

Wells Fargo

$128

Hold

-0.09%

Downside

Reiterated

10/12/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Pfizer (NYSE: PFE) and Incyte (NASDAQ: INCY)

Evan Seigerman

BMO Capital

$130

Hold

1.47%

Upside

Reiterated

10/12/26

BMO Capital Keeps Their Hold Rating on Incyte (INCY)

Tazeen Ahmad

Bank of America Securities

$140

Buy

9.27%

Upside

Reiterated

10/09/26

Incyte (INCY) Receives a Buy from Bank of America Securities

Brian Abrahams

RBC Capital

$109→$114

Hold

-11.02%

Downside

Reiterated

10/08/26

Incyte price target raised to $114 from $109 at RBC CapitalIncyte price target raised to $114 from $109 at RBC Capital

Stephen Willey

Stifel Nicolaus

$145→$157

Buy

22.54%

Upside

Reiterated

10/05/26

Incyte price target raised to $157 from $145 at StifelIncyte price target raised to $157 from $145 at Stifel

John Newman

Canaccord Genuity

$152

Buy

18.64%

Upside

Reiterated

10/01/26

Analysts Conflicted on These NA Names: Incyte (NASDAQ: INCY), Howard Hughes Holdings (NYSE: HHH) and Factset Research (NYSE: FDS)

Jessica Fye

J.P. Morgan

$120→$123

Hold

-4.00%

Downside

Reiterated

09/28/26

J.P. Morgan Reaffirms Their Hold Rating on Incyte (INCY)

Jeffrey Walch

Bernstein

$104

Hold

-18.83%

Downside

Reiterated

09/25/26

Incyte (INCY) Gets a Hold from Bernstein

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/19/26

Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties

Allison Bratzel

Piper Sandler

$110→$130

Buy

1.47%

Upside

Reiterated

08/17/26

Incyte price target raised to $130 from $110 at Piper SandlerIncyte price target raised to $130 from $110 at Piper Sandler

Andrew Berens

Leerink Partners

$131→$155

Buy

20.98%

Upside

Reiterated

08/03/26

Incyte price target raised to $155 from $131 at LeerinkIncyte price target raised to $155 from $131 at Leerink

Salim Syed

Mizuho Securities

$121→$137

Buy

6.93%

Upside

Reiterated

08/03/26

Mizuho Securities Remains a Buy on Incyte (INCY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

REPLReplimune Group

OVIDOvid Therapeutics

IMUXImmunic

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months

Michael SchmidtGuggenheim

Success Rate

19/25 ratings generated profit

Average Return

+10.05%

Copying Michael Schmidt's trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +10.05% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

17/19 ratings generated profit

Average Return

+29.00%

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +29.00% per trade.

2 Years

Tazeen AhmadBank of America Securities

Success Rate

17/19 ratings generated profit

Average Return

+34.85%

Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +34.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INCY has received 16 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. INCY average Analyst price target in the past 3 months is 131.70.

Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is -$3.51 with a range of -$4.46 to $1.93. The previous quarter’s EPS was $3.09. INCY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year INCY has Performed in-line its overall industry.

INCY Sales Forecast

Next quarter’s sales forecast for INCY is $1.47B with a range of $1.44B to $1.53B. The previous quarter’s sales results were $1.67B. INCY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year INCY has Performed in-line its overall industry.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 131.70.

What is INCY’s upside potential, based on the analysts’ average price target?

Incyte Corp has 2.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INCY a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy which is based on 11 buy ratings, 10 hold ratings and 0 sell ratings.

What is Incyte Corp’s price target?

The average price target for Incyte Corp is 131.70. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $157.00 ,the lowest forecast is $104.00. The average price target represents 2.79% Increase from the current price of $128.12.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of INCY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Incyte (INCY) Stock Forecast & Price Target

INCY Analyst Ratings

INCY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

INCY Analyst Recommendation Trends

INCY Financial Forecast

INCY Earnings Forecast

INCY Sales Forecast

INCY Stock Forecast FAQ

Detailed List of Analyst Forecasts